2-Deoxy-D-glucose (2-DG): Precision Glycolysis Inhibitor for Cancer, Viral & Metabolic Research

Executive Summary: 2-Deoxy-D-glucose (2-DG) is a synthetic glucose analog that competitively inhibits glycolysis, thereby lowering cellular ATP levels and inducing metabolic oxidative stress [APExBIO]. In vitro, 2-DG demonstrates cytotoxicity in KIT-positive gastrointestinal stromal tumor (GIST) cell lines, with reported IC50 values of 0.5 μM for GIST882 and 2.5 μM for GIST430 [APExBIO]. 2-DG impairs translation of viral proteins and inhibits replication of porcine epidemic diarrhea virus (PEDV) in Vero cells [APExBIO]. Animal model studies show that 2-DG enhances chemotherapeutic efficacy in human osteosarcoma and non-small cell lung cancer xenografts [Li et al., 2024]. The compound's solubility and storage characteristics are well-defined, supporting robust and reproducible experimental workflows.

Biological Rationale

Cellular metabolism is tightly regulated through glycolysis, with glucose serving as a central substrate for ATP production. Many cancer cells and virally infected cells exhibit increased glycolytic flux, known as the Warburg effect or metabolic reprogramming, to meet energy and biosynthetic demands [Li et al., 2024]. By targeting glycolytic pathways, researchers can disrupt tumor growth and viral replication. 2-Deoxy-D-glucose (2-DG) is a glucose analog that directly enters the glycolytic pathway but blocks further metabolism, leading to ATP depletion and metabolic stress. This approach is particularly relevant for studying PI3K/Akt/mTOR pathway modulation, where glycolysis and protein translation are interconnected [Li et al., 2024]. 2-DG also provides a research tool for dissecting metabolic dependencies in cancer, virology, and immunometabolic studies [See also: Precision Glycolysis Inhibition in Cancer].

Mechanism of Action of 2-Deoxy-D-glucose (2-DG)

2-DG is structurally similar to glucose but lacks a hydroxyl group at the 2-position, preventing its further metabolism after phosphorylation by hexokinase. The phosphorylated form, 2-DG-6-phosphate, accumulates and inhibits phosphoglucose isomerase, effectively blocking glycolytic flux [APExBIO]. This leads to:

• Reduced ATP synthesis and increased metabolic oxidative stress.
• Suppression of biosynthetic intermediates needed for cell proliferation.
• Altered redox balance and induction of apoptosis or necrosis in metabolically stressed cells.
• Impairment of glycosylation and protein translation, particularly in virally infected cells.

Recent research links glycolytic intermediates and lactate production to post-translational modifications such as α-tubulin lactylation, further connecting metabolism to cytoskeleton regulation and cell fate [Li et al., 2024].

Evidence & Benchmarks

• 2-DG exhibits cytotoxicity against KIT-positive GIST cell lines, with IC50 values of 0.5 μM for GIST882 and 2.5 μM for GIST430 under standard in vitro conditions (APExBIO).
• 2-DG impairs viral protein translation and inhibits PEDV replication in Vero cells at early infection stages (APExBIO).
• In animal xenograft models, 2-DG enhances Adriamycin and Paclitaxel efficacy, slowing tumor growth in human osteosarcoma and non-small cell lung cancer (Li et al., 2024).
• 2-DG is soluble at ≥105 mg/mL in water, ≥2.37 mg/mL in ethanol (with warming/ultrasonication), and ≥8.2 mg/mL in DMSO, supporting diverse experimental protocols (APExBIO).
• Typical in vitro experimental conditions use 5–10 mM 2-DG for 24 hours for robust glycolysis inhibition (APExBIO).
• Glycolysis inhibition by 2-DG can modulate PI3K/Akt/mTOR signaling and cytoskeleton function via lactate-dependent α-tubulin modifications (Li et al., 2024).

Applications, Limits & Misconceptions

2-Deoxy-D-glucose (2-DG) is widely adopted in several research domains:

• Cancer Metabolism: Used to dissect glycolytic dependencies in a range of solid and hematologic tumors [Earlier article: Validated Glycolysis Inhibitor]. This article extends by integrating post-translational metabolic links.
• Antiviral Research: Demonstrated to impair viral RNA/protein synthesis in PEDV and other RNA viruses.
• Immunometabolism: Applied to study T-cell and macrophage metabolic reprogramming [Redefining Translational Metabolomics]. Here, we clarify its selectivity via direct mechanistic benchmarks.
• Metabolic Pathway Mapping: Used as a probe for dissecting glycolysis, ATP synthesis, and downstream anabolic pathways.

Common Pitfalls or Misconceptions

• 2-DG is not a universal cytotoxin—cellular response depends on metabolic phenotype and glycolytic reliance.
• Not all viruses are sensitive to glycolytic inhibition; efficacy is virus- and cell-type dependent.
• Long-term storage of 2-DG solutions at room temperature leads to hydrolysis and potency loss—store at -20°C for stability.
• 2-DG does not directly inhibit mitochondrial oxidative phosphorylation.
• High concentrations (>20 mM) may induce off-target stress responses distinct from glycolytic inhibition.

Workflow Integration & Parameters

2-DG is typically prepared as a stock solution in water (≥105 mg/mL), ethanol with warming and ultrasonication (≥2.37 mg/mL), or DMSO (≥8.2 mg/mL) [APExBIO]. Recommended storage is at -20°C; avoid repeated freeze-thaw cycles. Standard in vitro treatment concentrations are 5–10 mM for 24 hours, though optimization may be required based on cell type and endpoint. For in vivo studies, dosing should align with published tolerability and pharmacokinetic data. The B1027 kit from APExBIO provides highly pure 2-DG suitable for these protocols. For translational workflows and troubleshooting, researchers can consult this workflow-focused guide, which this article updates by specifying new evidence linking 2-DG to post-translational cytoskeleton regulation.

Conclusion & Outlook

2-Deoxy-D-glucose (2-DG) is a rigorously validated tool for glycolysis inhibition, with application scope spanning cancer, viral, and metabolic research. Its mechanism—competitive inhibition of glycolysis and induction of metabolic oxidative stress—is now linked to regulation of post-translational modifications such as α-tubulin lactylation, further illuminating metabolism-cytoskeleton cross-talk. As research advances, 2-DG’s precise benchmarks and workflow compatibility, as offered by APExBIO, make it indispensable for next-generation studies in translational science.